Life Sciences

  • December 12, 2025

    Higgs Fletcher Forms White Collar, Regs Enforcement Team

    San Diego-based law firm Higgs Fletcher & Mack LLP has launched a white collar crime and regulatory enforcement defense practice group, citing heightened regulatory scrutiny in the financial and healthcare sectors and rising enforcement risks for licensed professionals and institutions.

  • December 11, 2025

    LA Bellwether Jury To Decide If J&J Hid Talc Risk For Decades

    An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a California jury Thursday in a bellwether trial's closing arguments that the company hid the health risks of talc for decades, while the company's attorney insisted the science is on their side.

  • December 11, 2025

    DC Circ. Oversees FDA Fight Over Generic IBS Drug

    Norwich Pharmaceuticals faced off against the U.S. Food and Drug Administration before the D.C. Circuit twice Thursday morning, both battles part of the drugmaker's five-year effort to bring a generic version of a prescription antibiotic used to treat irritable bowel syndrome to market.

  • December 11, 2025

    Tracking Challenges To USPTO's Discretion Policy

    Leaders at the U.S. Patent and Trademark Office have significantly altered the Patent Trial and Appeal Board playing field since March, making changes to institution reviews that have led to unprecedented levels of petition denials. A steady stream of companies has challenged those changes through mandamus petitions to the Federal Circuit, and here Law360 tracks where those petitions stand.

  • December 11, 2025

    Pharmacies Battle For Coverage Of Opioid Lawsuit Claims

    Publix Super Markets and a Georgia-based generic-drug wholesaler urged the Eleventh Circuit on Thursday to force their insurers to defend them in numerous lawsuits accusing the pharmacies of improperly distributing opioids, arguing their policies' coverage for "bodily injury" should include the suits.

  • December 11, 2025

    NC County Sues DuPont, 3M, Tyco Over PFAS Contamination

    A county in southeastern North Carolina is suing 3M Co., DuPont de Nemours Inc., the Chemours Co., Tyco Fire Products LP and other companies, alleging that they knowingly sold products containing PFAS, or "forever chemicals," that have contaminated county land.

  • December 11, 2025

    Elevance Health Adds Former Pfizer GC To Its Board

    Insurer Elevance Health has appointed former Pfizer Inc. general counsel Amy Schulman, currently a managing partner of Polaris Partners, to serve on its board of directors.

  • December 11, 2025

    Sidley Guides Diagnostic Imaging Firm Lumexa's $463M IPO

    Private equity-backed diagnostic imaging provider Lumexa Imaging Holdings Inc., led by Sidley Austin LLP, began trading Thursday on the Nasdaq Global Select Market after pricing a $463 million initial public offering.

  • December 11, 2025

    6th Circ. Panel Shows No Leanings On PBM Jurisdiction Fight

    A Sixth Circuit appeals panel gave few hints Thursday on whether it would send back to state court a lawsuit from Ohio alleging that pharmacy benefit managers were driving up prescription prices through rebate schemes. 

  • December 11, 2025

    4 Firms Guide As Arcline Exits Medical Tech Co. In $685M Deal

    Perimeter Solutions Inc. has agreed to acquire Medical Manufacturing Technologies LLC from Arcline Investment Management for approximately $685 million in cash, including certain tax benefits.

  • December 10, 2025

    Diagnostic Co. Agrees To Oversight Reforms In Derivative Suit

    A California federal judge has granted preliminary approval to a deal ending shareholder derivative claims that diagnostics company CareDx's executives and directors damaged the company by concealing its scheme to inflate its testing services revenue.

  • December 10, 2025

    Teva Pulls 200 Patents From Orange Book Amid FTC Probe

    The Federal Trade Commission said Wednesday an investigation it conducted into Teva Pharmaceuticals prompted the company to remove over 200 patents from the U.S. Food and Drug Administration's Orange Book.

  • December 10, 2025

    Apple Tells Fed. Circ. ITC Move Boosts Watch Case Appeal

    Apple Inc. has told the Federal Circuit that the U.S. International Trade Commission's decision last month to review whether a redesigned Apple Watch infringes Masimo Corp. patents "underscores the need" for the appeals court to reverse the ITC's original infringement finding.

  • December 10, 2025

    Med Delivery Co. Fired Workers For Pay Complaints, Suit Says

    A pharmaceutical delivery company misclassified drivers as independent contractors even though it controlled nearly every aspect of their work and fired 12 named drivers at once for speaking up about it, according to a proposed class action filed in Kentucky federal court.

  • December 10, 2025

    Akerman Hires DOJ Civil Division Lawyer For Healthcare Team

    Akerman LLP has brought on a former member of the U.S. Department of Justice's Civil Division, who will be joining the healthcare practice group as a partner in the firm's Washington, D.C., office, according to an announcement on Tuesday.

  • December 10, 2025

    VC Apple Tree Hits Ch. 11 After Row With Russian Billionaire

    Biotechnology investor Apple Tree Life Sciences Inc. and affiliates filed for Chapter 11 protection in Delaware bankruptcy court, days after a Chancery Court judge ordered a Russian billionaire who partnered with the fund to cough up $97 million that Apple Tree demanded to support its struggling medical companies.

  • December 10, 2025

    Weil, Reed Smith Build WTW's Newfront Buy For Up To $1.3B

    Advisory, brokerage and solutions company WTW, advised by Weil Gotshal & Manges LLP, announced Wednesday it had agreed to acquire Reed Smith LLP-led broker Newfront for up to $1.3 billion in a deal that will expand WTW's reach in the middle market and presence in technology, fintech and life sciences.

  • December 09, 2025

    Generic-Drug Group Backs House Bill On Skinny Labels

    An industry group representing the generic and biosimilar drug manufacturing sector has applauded the introduction of a U.S. House of Representatives bill titled The Skinny Labels, Big Savings Act, saying it will reduce prices across healthcare.

  • December 09, 2025

    Conn. Seems Open To Limits On Drug Price Cap Enforcement

    The state of Connecticut suggested Tuesday that drug sales to the state were not the same as drug sales "in this state" as defined by state law, a stance drug manufacturers promised to leverage in their efforts to block an impending drug price cap.

  • December 09, 2025

    NJ Drugmaker, Chubb Settle $6.5M Defense Costs Suit

    A New Jersey pharmaceutical company and Chubb have reached a settlement to end a lawsuit alleging the insurer owes nearly $6.5 million in outstanding legal fees stemming from a multibillion-dollar arbitration dispute over the development of a COVID-19 drug, according to a stipulation of dismissal from the companies. 

  • December 09, 2025

    Expert Invoices Discoverable In J&J Talc MDL, Judge Says

    A New Jersey federal judge said Monday that the plaintiffs steering committee can receive invoices for Johnson & Johnson's experts' work relating to multidistrict litigation alleging the use of talcum powder caused ovarian cancer and mesothelioma, but only after it produces its own expert invoices.

  • December 09, 2025

    Mistrial Declared In Fla. Opioid Case Against Pharmacies

    A Florida state judge declared a mistrial following a hung jury after two weeks of deliberations in a lawsuit brought by hospitals alleging that Walmart, Walgreens and CVS pharmacies negligently doled out painkillers and contributed to the opioid crisis. 

  • December 09, 2025

    Hagens Berman's Novel DOJ Referral May Have Chilling Effect

    A Pennsylvania federal judge's unusual decision to refer prominent plaintiffs firm Hagens Berman LLP to the U.S. Department of Justice for possible criminal investigation over its pursuit of claims related to morning sickness drug thalidomide could have a chilling effect on lawyers' advocacy, law professors and attorneys said.

  • December 09, 2025

    Medical Appliance Co. Seeks Coverage For SEC Investigation

    A Connecticut-based medical device technology company told a federal court that its insurer wrongfully denied coverage for an investigation by the Securities and Exchange Commission, alleging in a new lawsuit that the federal government's inquiry into the company's insured members triggered its directors and officers policy. 

  • December 09, 2025

    Cooley Adds 30-Person Life Sciences IP Team From Dechert

    A trio of Dechert LLP partners, including the co-chair of its global intellectual property practice, have joined Cooley LLP alongside a team of special counsel, associates and patent agents, the firm announced Tuesday.

Expert Analysis

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Patent Claim Lessons From Fed. Circ.'s Teva Decision

    Author Photo

    The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.

  • Series

    Law School's Missed Lessons: Adapting To The Age Of AI

    Author Photo

    Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.

  • Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning

    Author Photo

    A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.

  • DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech

    Author Photo

    The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.

  • Future-Proof Patent Law By Starting Talent Pipelines Early

    Author Photo

    Law firms struggling with a narrow talent pipeline in the intellectual property space should consider beginning their recruitment strategies for potential candidates as early as high school, and raise awareness for career opportunities that do not require a law degree, says Christine Hollis at Marshall Gerstein.

  • Demystifying The Civil Procedure Rules Amendment Process

    Author Photo

    Every year, an advisory committee receives dozens of proposals to amend the Federal Rules of Civil Procedure, most of which are never adopted — but a few pointers can help maximize the likelihood that an amendment will be adopted, says Josh Gardner at DLA Piper.

  • How USPTO Examiner Memo Informs Software Patent Drafting

    Author Photo

    A memorandum recently released by the U.S. Patent and Trademark Office provides useful clues as to how the USPTO and examining corps will evaluate claims in software-implemented inventions for subject matter eligibility going forward, says Michael Lew at Squire Patton.

  • How 2nd Circ. Cannabis Ruling Upends NY Licensing

    Author Photo

    A recent Second Circuit decision in Variscite NY Four v. New York, holding that New York's extra-priority cannabis licensing preference for applicants with in-state marijuana convictions violates the dormant commerce clause, underscores that state-legal cannabis markets remain subject to the same constitutional constraints as other economic markets, say attorneys at Harris Beach.

  • Parenting Skills That Can Help Lawyers Thrive Professionally

    Author Photo

    As kids head back to school, the time is ripe for lawyers who are parents to consider how they can incorporate their parenting skills to build a deep, meaningful and sustainable legal practice, say attorneys at Alston & Bird.

  • Enablement Standard Insights From Fed. Circ. Agilent Ruling

    Author Photo

    The Federal Circuit's recent enablement standard decision in Agilent v. Synthego underscores three critical takeaways for patent practitioners, including reaffirmation that the enablement inquiry under Section 102 of the Patent Act is distinct from the inquiry under Section 112, say attorneys at MoFo.

  • Series

    Teaching Trial Advocacy Makes Us Better Lawyers

    Author Photo

    Teaching trial advocacy skills to other lawyers makes us better litigators because it makes us question our default methods, connect to young attorneys with new perspectives and focus on the needs of the real people at the heart of every trial, say Reuben Guttman, Veronica Finkelstein and Joleen Youngers.

  • The Crucial Question Left Unanswered In EpicentRx Decision

    Author Photo

    The California Supreme Court recently issued its long-awaited decision in EpicentRx Inc. v. Superior Court, resolving a dispute regarding the enforceability of forum selection clauses, but the question remains whether private companies can trust that courts will continue to consistently enforce forum selection clauses in corporate charters, says John Yow at Yow PC.

  • Federal AI Action Plan Marks A Shift For Health And Bio Fields

    Author Photo

    The Trump administration's recent artificial intelligence action plan significantly expands federal commitments across biomedical agencies, defining a pivotal moment for attorneys and others involved in research collaborations, managing regulatory compliance and AI-related intellectual property, says Mehrin Masud-Elias at Arnold & Porter.

  • Preparing For DEA Rescheduling Of 2 Research Chemicals

    Author Photo

    A recent decision to allow the U.S. Drug Enforcement Administration to reclassify two research psychedelics in Schedule I under the Controlled Substances Act may pose significant barriers to scientific study, including stringent registration requirements, heightened security protocols and burdensome reporting obligations, say Kimberly Chew at Husch Blackwell and Jackie von Salm at Psilera.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.